Skip to main content
Back
LBTSF logo

Almirall, S.A.

Data quality: 100%
Oversold
LBTSF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$15.35
▼ $0.12 (-0.78%)
Mkt Cap: 3.29B
Day Range
$15.35 $15.35
52-Week Range
$9.01 $15.47
Volume
100
50D / 200D Avg
$14.96 / $12.80
Prev Close
$15.47

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (625 peers)

Metric Stock Sector Median
P/E 71.3 14.0
P/B 2.2 2.4
ROE % 3.1 11.4
Net Margin % 4.2 10.1
Rev Growth 5Y % 7.6 7.0
D/E 0.2 0.5

Key Takeaways

Revenue grew 7.57% annually over 5 years — modest growth
Earnings grew 355.14% over the past year
ROE of 3.10% is below average
Debt/Equity of 0.23 — conservative balance sheet
Generating 134.24M in free cash flow
P/E of 71.34 — premium valuation

Growth

Revenue Growth (5Y)
7.57%
Revenue (1Y)12.37%
Earnings (1Y)355.14%
FCF Growth (3Y)N/A

Quality

Return on Equity
3.10%
ROIC2.77%
Net Margin4.17%
Op. Margin6.11%

Safety

Debt / Equity
0.23
Current Ratio2.04
Interest Coverage3.79

Valuation

P/E Ratio
71.34
P/B Ratio2.22
EV/EBITDA48.75
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12.37% Revenue Growth (3Y) 11.28%
Earnings Growth (1Y) 355.14% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 7.57% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.11B Net Income (TTM) 46.18M
ROE 3.10% ROA 1.98%
Gross Margin 41.21% Operating Margin 6.11%
Net Margin 4.17% Free Cash Flow (TTM) 134.24M
ROIC 2.77% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.23 Current Ratio 2.04
Interest Coverage 3.79 Dividend Yield 0.01%
Valuation
P/E Ratio 71.34 P/B Ratio 2.22
P/S Ratio 2.97 PEG Ratio 0.16
EV/EBITDA 48.75 Dividend Yield 0.01%
Market Cap 3.29B Enterprise Value 3.30B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.11B 985.72M 894.52M 863.25M 827.20M
Net Income 46.18M 10.15M -38.47M 4.28M -40.86M
EPS (Diluted) 0.21 0.05 -0.20 0.02 -0.23
Gross Profit 456.47M 767.68M 682.04M 680.78M 655.61M
Operating Income 67.69M 36.09M -5.26M 46.87M 5.75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.34B 2.40B 2.37B 2.15B 2.14B
Total Liabilities 829.43M 908.28M 911.59M 828.98M 855.71M
Shareholders' Equity 1.49B 1.49B 1.46B 1.32B 1.29B
Total Debt 342.86M 408.81M 403.25M 403.88M 396.11M
Cash & Equivalents 337.64M 377.10M 387.95M 248.38M 206.49M
Current Assets 713.72M 741.14M 718.66M 552.72M 499.27M
Current Liabilities 350.51M 353.42M 351.08M 274.61M 280.99M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#776 of 1018
32

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026